Sanofi-Aventis is the latest major drugmaker to confirm that it is trimming its sales force in the USA.

Three days after Chris Viehbacher took over from Gerard Le Fur as chief executive, the French company is reducing its sales force across the Atlantic, which is currently around 6,500-strong. The number is expected to be reduced by a single-digit percentage, but Sanofi, which has its US base in Bridgewater, New Jersey, is not giving out any specific figures nor where exactly the cuts are happening.

Sanofi says that the re-alignment of its sales force forms part of a “new commercial model designed to deliver greater value to our customers in a rapidly changing business environment”.

The Paris-based firm joins GlaxoSmithKline, Pfizer, Merck & Co, Novartis, Schering-Plough and Wyeth in cutting reps in the USA. This year alone, over 6,000 field force jobs have been eliminated.